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OBJECTIVE—To examine whether serum 25-hydroxyvitamin D (25OHD) and dietary cal-
cium predict incident type 2 diabetes and insulin sensitivity.
RESEARCH DESIGN AND METHODS—Atotal of 6,537of the 11,247 adults evaluated
in1999–2000intheAustralianDiabetes,ObesityandLifestyle(AusDiab)study,returnedfororal
glucose tolerance test (OGTT) in 2004–2005. We studied those without diabetes who had
completedataatbaseline(n=5,200;meanage51years;55%werewomen;92%wereEuropids).
Serum 25OHD and energy-adjusted calcium intake (food frequency questionnaire) were
assessed at baseline. Logistic regression was used to evaluate associations between serum
25OHD and dietary calcium on 5-year incidence of diabetes (diagnosed by OGTT) and insulin
sensitivity (homeostasis model assessment of insulin sensitivity [HOMA-S]), adjusted for mul-
tiple potential confounders, including fasting plasma glucose (FPG).
RESULTS—Duringthe5-yearfollow-up,199incidentcasesofdiabeteswerediagnosed.Those
who developed diabetes had lower serum 25OHD (mean 58 vs. 65 nmol/L; P , 0.001) and
calcium intake (mean 881 vs. 923 mg/day; P = 0.03) compared with those who remained free of
diabetes. Each25 nmol/Lincrement inserum25OHDwas associatedwith a24%reducedrisk of
diabetes (odds ratio 0.76 [95% CI 0.63–0.92]) after adjusting for age, waist circumference,
ethnicity, season, latitude, smoking, physical activity, family history of diabetes, dietary magne-
sium, hypertension, serum triglycerides, and FPG. Dietary calcium intake was not associated
with reduced diabetes risk. Only serum 25OHD was positively and independently associated
with HOMA-S at 5 years.
CONCLUSIONS—Higher serum 25OHD levels, but not higher dietary calcium, were asso-
ciated with a signiﬁcantly reduced risk of diabetes in Australian adult men and women.
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ccumulating evidence suggests that
vitamin D deﬁciency is associated
with an increased risk of developing
type 2 diabetes (1–3). Animal andhuman
studies indicate that vitamin D can have a
direct (via activation of the vitamin D
receptor on pancreatic b-cells and insulin-
sensitive organs) and indirect (via regula-
tion of calcium homeostasis) positive
effect on insulin secretion and sensitivity
(3,4). Several prospective studies also
support the hypothesis that low vitamin
D status is a risk factor for the develop-
ment of type 2 diabetes (1–3,5,6); how-
ever, these studies were limited by small
study sample sizes (3), indirect measures
of vitamin D status as a surrogate marker
(6,7), and incomplete identiﬁcation of
incident diabetes cases (1,2,5). In addi-
tion, most did not include an assessment
of dietary calcium, which may have an
independent or synergistic effect with vi-
tamin D on lowering type 2 diabetes risk
(7). The aim of this study was to examine
the relationship between serum 25-
hydroxyvitamin D (25OHD), dietary cal-
cium, and risk of developing type 2
diabetes as assessed by an oral glucose
tolerance test (OGTT) in a large national,
population-based prospective study: the
Australian Diabetes, Obesity and Lifestyle
(AusDiab) study.
RESEARCH DESIGN AND
METHODS
Subjects
T h eb a s e l i n e( 1 9 9 9 –2000) and follow-up
(2004–2005) AusDiab studies were de-
signed to determine the prevalence and
incidence of type 2 diabetes and predia-
betes throughout Australia using the
World Health Organization 1999 criteria
for a 75-g OGTT. Further details of these
studies have been described (8). Brieﬂy,
20,347 noninstitutionalized adults aged
$25yearsfrom42randomlyselecteddis-
tricts completed a household interview in
1999–2000, of whom 11,247 (55.3%)
attended a biomedical evaluation, includ-
ing an OGTT after an overnight fast. Five
years later, 6,537 adults returned for a re-
peat OGTT. Of those, 5,200 were free of
diabetes at baseline and with complete
data (54.7% were women). Written in-
formed consent was obtained from all
participants, and ethical approval was
provided by the International Diabetes
Institute Ethics Committee and the
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Measurements
Assessment of vitamin D status and
dietary calcium intake. Samples were
stored at 280°C until assayed. Serum
2 5 O H Dw a sm e a s u r e di nt h ee n t i r e
AusDiab population at baseline (n =
11,218, excluding 29 without any speci-
men available) using the Liaison25OH
vitamin D TOTAL (Liaison25OHD)
(DiaSorin Inc., Stillwater, MN), a direct
competitive chemiluminescent immuno-
assay with an interassay coefﬁcient of var-
iation of 7.0% at 45 nmol/L and 6.3% at
93 nmol/L in our laboratory. In 210 sam-
ples where fasting serum were not avail-
able, ﬂu o r i d eo x a l a t ep l a s m a( f a s t i n g
plasma n = 190; 2-h plasma post-OGTT
n=20)wasused.We foundthattherewas
excellent agreement between serum
25OHD levels collected from both tubes
(n = 100): ﬂuoride oxalate plasma
25OHD = 0.97 3 serum 25OHD + 2.5,
r
2 = 0.89 (data not shown). Season of
blood sampling was divided into autumn–
winter (April to September) and spring–
summer (October to March). The latitude
ofeachbloodcollectioncenterwasdeter-
mined using the Google GPS tool (range
12–43°S).
Total energy, dietary calcium, magne-
sium, and alcohol intakes were assessed
using a self-administered validated food
frequency questionnaire as reported pre-
viously (8). Calculation of nutrient intake
was achieved by multiplying the fre-
quency of consumption by standard
portion weights, which were then con-
verted into nutrient intakes based on the
NUTTAB95nutrientcompositiondatabase
(Food Standards Australia New Zealand,
Canberra). Dietary intakes of calcium and
magnesium were adjusted for total energy
intake by using the residual method (9).
Ascertainment of incident diabetes. In-
cident diabetes at follow-up was deﬁned
by treatment with insulin or oral hypo-
glycemic agents, fasting plasma glucose
(FPG) $7 mmol/L or 2-h plasma glucose
(PG) post-OGTT $11.1 mmol/L.
Risk factors of type 2 diabetes. Data on
risk factors, including age, sex, ethnicity
(Europid and non-Europid), smoking
(current and ex/nonsmoker), leisure-
time physical activity (PA), education,
and family history of type 2 diabetes,
were collected by trained interviewers
using standardized questionnaires as pre-
viously reported (8). Total leisure-time
PA reported for the previous week was
calculated using the validated Active
Australia questionnaire. Total time spent
watching television or videos in the pre-
vious 7 days was self-reported. Height,
weight, waist circumference (WC), and
blood pressure were assessed using
standard procedures as previously de-
scribed (8). Hypertension at baseline
wasdeﬁnedasasystolicordiastolicblood
pressure $140 or $90 mmHg, respec-
tively, or self-reported use of antihyper-
tensive medication.
FPG and 2-h PG were measured at
baseline by a glucose oxidase method,
and serum total cholesterol, triglycerides,
and HDL-cholesterol were measured by
enzymatic methods using an Olympus
AU600 automated analyzer (Olympus
Optical, Tokyo, Japan). Serum insulin was
measured using a human insulin-speciﬁc
radioimmunoassay (Linco Research,
St. Charles, MO). Insulin sensitivity was
estimated from FPG and fasting insulin
using homeostasis model assessment
(HOMA). HOMA of insulin sensitivity
(HOMA-S) was calculated with the
HOMA-2 program (10).
Statistical analysis. Analyses were per-
formed using SPSS 17.0 (SPSS Inc.,
Chicago, IL) and Stata Statistical Software
version 10.1 (StataCorp, College Station,
TX). Variables that were not normally
distributed were log-transformed before
analysis (total energy and magnesium
intake, serum triglycerides, and HOMA-S).
Baseline characteristics between incident
cases and those who did not develop
diabetes were compared using a x
2 test
(categoric variables) and independent t test
or Mann-Whitney U test (continuous
variables). Logistic regression was used
to calculate odds ratios (ORs) with 95%
CIs for the association between serum
25OHD or calcium intake and diabetes
risk. Serum 25OHD and calcium intake
were entered as continuous variables and
reported per increment of 25 nmol/L of
serum 25OHD or 200 mg/day of calcium.
Quartiles of serum 25OHD and di-
etary calcium were also analyzed using
logistic regression for categoric variables,
with tests of linear trend conducted by
assigning median values of 25OHD or
calcium in quartiles as a continuous vari-
able. No interaction was found among
sex, ethnicity, and serum 25OHD or
calcium intake for any of the outcome
measures. The test for colinearity (vari-
ance inﬂation factor) was 1.07 and 1.01
for serum 25OHD and calcium intake,
respectively (11). To ensure that the rela-
tionship among serum 25OHD, calcium
intake, and incident diabetes was linear,
the squared term of serum 25OHD and
calcium intake was calculated, and a lo-
gisticregressionmodelincludingage,sea-
son, latitude, and serum 25OHD (or age
and calcium intake) was compared with a
model including age, season, latitude, se-
rum 25OHD (or age and calcium intake),
and squared term of serum 25OHD (or
calcium intake). Tests for linearity were
examined using the likelihood ratio test
by comparing the model with only the
linear term added with the model with
the linear and squared terms. Linearity
was also tested by plotting the adjusted
O R sb yq u i n t i l e so fs e r u m2 5 O H Da n d
calcium intake.
Univariate analysis of the following
variables was conducted to identify sig-
niﬁcant predictors of diabetes incidence:
age, sex, WC,ethnicity,education, smok-
ing, magnesium and alcohol intake, fam-
ily history of diabetes, PA, hypertension,
triglycerides, HDL- and LDL- cholesterol,
and television viewing time. Variables
with a P , 0.1 were then entered into
the model, with the least signiﬁcant re-
moved manually in a backward stepwise
fashion. Variables with a P # 0.05 were
enteredintheﬁnalregressionmodels,but
all analyses that included serum 25OHD
were adjusted for season and latitude.
Model 1 included age, WC, ethnicity,
family history of diabetes, smoking, and
PA. Model 2 included model 1 plus hyper-
tension and serum triglycerides. Model 3
included model 2 plus magnesium intake.
Model 4 included model 2 plus FPG.
Finally, both serum 25OHD and calcium
intake wereentered together into model 4.
Linear regression analysis was used to ex-
amine the associations between serum
25OHD and calcium intake and HOMA-S
after adjusting for the confounders in
models 1–4.
RESULTS
Serum 25OHD, dietary calcium
intake, and risk factors of type 2
diabetes at baseline
Overall, 199 incident cases of diabetes
(3.8%) developed during follow-up.
Those who developed diabetes were
older, had a higher WC, were more likely
to be current smokers and lead a seden-
tary lifestyle, have a family history of
diabetes, be of non-Europid origin, and
belesseducatedthanthosewhoremained
free of diabetes (Table 1). Mean serum
25OHD concentrations and dietary cal-
cium and magnesium intakes were also
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Vitamin D, calcium, and type 2 diabetes risksigniﬁcantly lower in those who devel-
oped diabetes.
Associations among serum 25OHD,
dietary calcium intake, and risk of
type 2 diabetes
Baseline serum 25OHD was indepen-
dently and inversely associated with
5-year type 2 diabetes risk. For each
25 nmol/L increment in serum 25OHD,
diabetes risk was reduced by 29% after
adjusting for the confounders in model 1
(OR 0.71 [95% CI 0.59–0.85]). The in-
clusion of additional covariates in model
1d i dn o ts i g n i ﬁcantly change the results:
hypertension and serum triglycerides
(model 2: OR 0.78 [0.64–0.93]), magne-
sium intake (model 3: OR 0.78 [0.65–
0.94]), or FPG (model 4: OR 0.76
[0.63–0.92]). Adding a squared term for
serum 25OHD to the model with serum
25OHD, age, season, and latitude did not
signiﬁcantly improve the prediction for
diabetes incidence (likelihood ratio P =
0.24), which indicates that the rela-
tionship between 25OHD and diabetes
incidence was linear. Dietary calcium was
not associated with diabetes risk in any of
the models (model 1: OR 0.94 [0.84–
1.05]); model 2: OR 0.95 [0.84–1.06]);
model 3: OR 0.99 [0.88–1.12]); model 4:
OR 0.97 [0.86–1.09]).
When we repeated the analysis by
quartiles, the OR comparing the highest
versus the lowest quartile of serum
25OHD in model 1 was 0.56 (95% CI
0.36–0.86;P =0.001 for trend) (Table 2).
When further adjustments were made for
other potential confounders in models
2–4, the signiﬁcantly lower risk of diabe-
tes incidence persisted across quartiles.
There was no association between quar-
tiles of dietary calcium and diabetes risk
(Table 2). When both serum 25OHD and
dietary calcium intake were entered to-
gether as continuous variablesintomodel
4, serum 25OHD remained a signiﬁcant
independent predictor of diabetes risk
(OR 0.76 [0.63–0.92]). There was no in-
teraction between serum 25OHD and di-
etary calcium on diabetes risk (P = 0.14).
Associations among serum 25OHD,
calcium intake, and insulin
sensitivity
There was a signiﬁcant positive associa-
tion between baseline serum 25OHD and
HOMA-S at 5 years (r =0 . 1 6 ,P , 0.001).
Serum 25OHD remained a signiﬁcant in-
dependent predictor of HOMA-S at
5yearsafteradjustmentfortheconfound-
e r si nm o d e l s1 –4( T a b l e3 ) ,a n dw h e n
both serum 25OHD and dietary calcium
were entered together into the models.
Baseline dietary calcium intake was
not associated with HOMA-S at 5 years
(Table 3).
CONCLUSIONS—Our study is the
ﬁrst large population-based prospective
study to have investigated the association
between vitamin D status and type 2 di-
abetes risk by measuring serum 25OHD
and by identifying both diagnosed and
undiagnosed incident diabetes cases by
OGTT. In this nationally representative
cohortofAustralianadults,wehaveshown
that higher serum 25OHD concentrations
were associated with a reduced risk of
developing type 2 diabetes at 5 years.
Each 25 nmol/L increment in serum
25OHD was associated with a 22–29%
risk reduction of type 2 diabetes. This
was independent of well-known risk
factors for type 2 diabetes and insulin
sensitivity including FPG, which forms
part of the deﬁnition of diabetes by
OGTT.Becausethisﬁndingisconsistent
with the results from previous studies
using different methods to measure di-
abetes incidence (1–3,5,6), it fulﬁlls one
o ft h ec a u s a lc r i t e r i ab yB r a d f o r d - H i l l
and thus adds to the body of evidence
linking vitaminD deﬁciency with diabetes.
We have also shown that the relationship
between serum 25OHD and type 2 diabe-
tes risk is linear and independent of dietary
calcium. Moreover, serum 25OHD was
positively and independently associated
with HOMA-S, a marker of insulin sensi-
tivity. In contrast, dietary calcium intake
was not associated with either HOMA-S
or type 2 diabetes risk.
The ﬁnding of an inverse association
between serum 25OHD and type 2 di-
abetes risk in our study is consistent with
the results from several prospective ob-
servationalstudies (1,2,6). We found that
individuals in the third and fourth quar-
tiles of serum 25OHD (median 70 and 93
nmol/L, respectively) had a 57 and 44%
risk reduction, respectively, of develop-
ing type2 diabetes over 5 yearscompared
with individuals in the lowest quartile
(median 40 nmol/L), after adjusting for
traditional risk factors. Similar results
were reported in a pooled, nested case-
control analysis of two Finnish cohort
studies that included more than 7,500
m e na n dw o m e na g e d4 0 –74 years at
baseline who were followed for 17–22
years (2). In this study, men but not
Table 1—Baseline characteristics of participants by diabetes status at 5 years
Characteristic Diabetes No diabetes P value*
N 199 5,001
Age (years) 55.6 6 11.9 50.6 6 12.5 ,0.001
Women, n (%) 97 (48.7) 2,748 (54.9) 0.10
Europids, n (%) 175 (87.9) 4,609 (92.2) 0.03
University/TAFE, n (%) 66 (33.2) 2,118 (42.4) 0.01
Family history of diabetes, n (%) 64 (32.2) 907 (18.1) ,0.001
BMI (kg/m
2)2 9 . 4 6 5.6 26.5 6 4.5 ,0.001
WC (cm) 98 6 14 89 6 13 ,0.001
Current smoking, n (%) 34 (17.1) 549 (11.0) 0.01
Alcohol intake (g/day) 5.3 (0.9–23.3) 6.8 (1.0–19.4) 0.82
PA (min/week) 120 (20–270) 180 (45–420) ,0.001
Television viewing time (min/week) 720 (420–1,140) 660 (330–960) 0.04
Hypertension, n (%) 105 (52.8) 1,343 (26.9) ,0.001
Serum FPG (mmol/L) 5.9 6 0.6 5.3 6 0.5 ,0.001
Serum 2-h PG (mmol/L) 7.9 (6.7–9.4) 5.6 (4.8–6.7) ,0.001
Serum triglycerides (mmol/L) 1.7 (1.2–2.5) 1.2 (0.8–1.7) ,0.001
Serum HDL-cholesterol (mmol/L) 1.3 6 0.4 1.5 6 0.4 ,0.001
Serum LDL-cholesterol (mmol/L) 3.6 6 0.9 3.5 6 0.9 0.08
Sampling winter, n (%) 108 (54.3) 2,991 (59.8) 0.12
Serum 25OHD (nmol/L) 58 6 23 65 6 25 ,0.001
Total energy intake (kJ/day) 7,401 (5,905–9,016) 7,673 (6,021–9,711) 0.08
Dietary calcium intake (mg/day) 881 6 260 923 6 263 0.03
Dietary magnesium intake (mg/day) 286 (256–328) 297 (263–337) 0.03
Data are presented as mean 6 SD, median (interquartile range), or n (%). Intakes of calcium and magnesium
are adjusted for total energy intake. TAFE, Technical and Further Education. *Independent t test or Mann-
Whitney U test for continuous variables; x
2 test for categoric variables.
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Gagnon and Associateswomen in the highest versus lowest quar-
tile of serum 25OHD (mean 75 vs. 25
nmol/L) had a 72% lower risk of type 2
diabetes after adjusting for age, BMI, PA,
smoking, and education. Family history
of diabetes was not accounted for, and
because the incident cases were identiﬁed
through a diabetes medication registry,
contamination of the control subjects
with people who may have had diet-
controlled or undiagnosed diabetes
may explain the inconsistent results be-
tween men and women. Pittas et al. (1)
publishedacase-controlstudyconducted
among 608 women with self-reported
newly diagnosed type 2 diabetes and
559 control subjects nested within the
Nurses’ Health Study. They reported
that the risk of incident diabetes was
48% lower in women in the highest ver-
sus lowest serum 25OHD quartile (me-
dian 84 vs. 36 nmol/L) independently of
known diabetes risk factors and dietary
calcium and magnesium intake. How-
ever, self-report of both diabetes and
risk factors for diabetes, such as BMI,
hypertension, and hypercholesterolemia,
may have underestimated the incidence
of diabetes and the prevalence of these
risk factors. Despite this, their ﬁndings
were similar to ours. Finally, Liu et al.
(6) reported that type 2 diabetes inci-
dence was 40% lower at 7 years in indi-
viduals in the highest versus lowest tertile
of predicted serum 25OHD (median
55 vs. 42 nmol/L) after adjustment for
multiple risk factors, including impaired
FPG.However,thisstudyislimitedbythe
use of a predicted serum 25OHD score,
whichonlyexplained26%ofthevariance
in measured serum 25OHD levels. In ad-
dition,type2diabetesincidentcaseswere
likelyunderestimated,becauseusingFPG
alone would miss a signiﬁcantproportion
of cases identiﬁable with 2-h PG. In our
study,46%oftheparticipantshadanFPG
,7mmol/Landa2-hPG$11.1mmol/L.
Given these limitations, our study pro-
vides the strongest evidence to date to
support the hypothesis that higher circu-
lating25OHDlevelsareprotectiveagainst
the development of type 2 diabetes.
The small number of prospective
studies investigating the association be-
tweendietary calciumandtype2diabetes
risk have produced mixed results
(7,12,13). In our study, baseline dietary
calcium intake was not associated with
type 2 diabetes risk. Similar ﬁndings
werereportedintheNurses’HealthStudy
(7); however, a supplemental calcium in-
take of .500 mg/day or a total calcium
intake (diet plus supplements) of .1,200
mg/daywasassociatedwithasigniﬁcantly
reduced risk of developing diabetes inde-
pendentlyofother dietaryfactors,includ-
ing vitamin D intake. Because calcium
supplement use was not assessed in our
study, we were unable to differentiate be-
tween the speciﬁc roles of dietary and
supplemental calcium on diabetes risk.
This may be important because others
have reported an inverse association be-
tween dairy intake and type 2 diabetes in-
cidence (12–14).
The beneﬁcial effects of higher circu-
lating 25OHD levels on reducing type 2
Table 2—ORs of developing type 2 diabetes at 5 years by quartiles of serum 25OHD and dietary calcium intake
Quartile n
Incident
cases, n (%)
ORs (95% CI)
Model 1* Model 2† Model 3‡ Model 4§
Serum 25OHD (range in nmol/L)
1( 9 –48) 1,223 71 (5.8%) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
2( 4 9 –63) 1,324 56 (4.2%) 0.76 (0.52–1.10) 0.81 (0.55–1.17) 0.81 (0.56–1.18) 0.83 (0.56–1.22)
3( 6 4 –78) 1,348 34 (2.5%) 0.43 (0.28–0.67) 0.49 (0.31–0.75) 0.50 (0.32–0.77) 0.48 (0.31–0.76)
4( 7 9 –233) 1,305 38 (2.9%) 0.56 (0.36–0.86) 0.68 (0.44–1.06) 0.70 (0.45–1.09) 0.68 (0.43–1.07)
P for trend 0.001 0.02 0.03 0.02
Dietary calcium intake (range in mg/day)¶
1( 1 7 1 –740) 1,300 58 (4.5%) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
2( 7 4 1 –885) 1,300 62 (4.8%) 1.24 (0.85–1.81) 1.24 (0.85–1.81) 1.27 (0.87–1.86) 1.21 (0.82–1.79)
3( 8 8 6 –1,059) 1,300 39 (3.0%) 0.76 (0.50–1.17) 0.77 (0.51–1.19) 0.84 (0.54–1.29) 0.87 (0.56–1.35)
4( 1 , 0 6 0 –2,317) 1,300 40 (3.1%) 0.86 (0.56–1.32) 0.90 (0.59–1.38) 1.04 (0.67–1.63) 0.94 (0.61–1.46)
P for trend 0.19 0.28 0.74 0.49
*Model 1: adjusted for age, ethnicity, WC, family history of diabetes, smoking status, and PA (plus season and latitude for serum 25OHD). †Model 2: model 1 plus
hypertension and serum triglycerides. ‡Model 3: model 2 plus energy-adjusted magnesium intake. §Model 4: model 2 plus FPG. ¶Energy-adjusted calcium intake.
Table 3—Association between serum 25OHD level and dietary calcium intake
with insulin sensitivity (HOMA-S)
Log insulin sensitivity (HOMA-S)
Outcome per 25 nmol/L
increase in serum 25OHD
Outcome per 200 mg/day
increase in dietary calcium¶
Model 1* B (95% CI) 0.083 (0.068–0.099) 0.003 (20.007 to 0.014)
P value ,0.001 0.53
Adjusted R
2 0.31 0.29
Model 2† B (95% CI) 0.063 (0.048–0.078) 0.001 (20.010 to 0.011)
P value ,0.001 0.88
Adjusted R
2 0.34 0.33
Model 3‡ B (95% CI) 0.060 (0.045–0.075) 20.008 (20.019 to 0.003)
P value ,0.001 0.13
Adjusted R
2 0.35 0.34
Model 4§ B (95% CI) 0.063 (0.048–0.078) 0.000 (20.011 to 0.010)
P value ,0.001 0.97
Adjusted R
2 0.35 0.34
B, bcoefﬁcient.*Model 1:adjustedforage,ethnicity,WC,familyhistoryofdiabetes,smokingstatus,andPA
(and season and latitude for serum 25OHD). †Model 2: model 1 plus hypertension and serum triglycerides.
‡Model 3: model 2 plus energy-adjusted magnesium intake. §Model 4: model 2 plus FPG. ¶Energy-adjusted
calcium intake.
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Vitamin D, calcium, and type 2 diabetes riskdiabetesriskmayberelatedtoitseffecton
promoting b-cell function and insulin
sensitivity (4,15). We found that higher
serum 25OHD levels were associated
with improved insulin sensitivity, as as-
sessed by HOMA-S. In nondiabetic men
and women aged 40–69 years, Forouhi
et al. (3) reported that each 25 nmol/L
increase in baseline 25OHD was associ-
ated with a 0.16-unit decrease in HOMA
of insulin resistance at 10 years. Several
cross-sectional studies have also reported
an inverse association between serum
25OHD and measures of insulin resis-
t a n c e( 1 5 )a n dap o s i t i v ea s s o c i a t i o n
with measures of insulin sensitivity
(4,15). Evidence from in vitro studies
suggests that vitamin D may alter insulin
sensitivity via a direct stimulatory effect
oninsulinreceptorexpression(16),mod-
ulation of inﬂammation (17), and adipo-
nectin levels (18).T w or a n d o m i z e d
controlled trials of high-dose vitamin D
supplementation in either insulin-resistant
Indian men or South-Asian women
showed signiﬁcant increases in insulin
sensitivity after 6 weeks or 6 months of
treatment, respectively (19,20). Our ﬁnd-
ings therefore add to the current literature
suggesting that vitamin D may play a role
in the prevention of type 2 diabetes by
improving insulin sensitivity. Although
in vitro studies suggest that calcium may
improve insulin sensitivity by increasing
the binding afﬁnity of insulin to its recep-
tor and promoting insulin-mediated glu-
cose transport in adipocytes (21,22), we
found no association between dietary cal-
cium and insulin sensitivity. However,
othershavereportedapositiveassociation
between dietary calcium and 5-year insu-
lin sensitivity, as assessed by the intrave-
nous glucose tolerance test (23), and an
improvement in insulin sensitivity after
the daily administration of 1,500 mg of
calcium in patients with type 2 diabetes
and hypertension (24). It is therefore pos-
sible that supplemental calcium may im-
prove insulin sensitivity, but randomized
controlled trials are needed to address this
question.
Our study has several limitations.
First, serum 25OHD was only measured
at baseline, which may not reﬂect long-
term vitamin D status. However, data
from a 14-year prospective study showed
that serum 25OHD levels track within
z score quintiles, especially for those with
the highest and lowest levels (25). Second,
no information was collected on the use of
calcium and vitamin D supplements, and
thus we could not discriminate between
the effects of dietary and supplemental
calcium or vitamin D on diabetes risk.
Third, because .90% of our cohort was
Europid, our results cannot be directly ex-
trapolated to other race/ethnic groups.
Fourth,becauseoftheobservationaldesign
ofthisstudy,residualconfoundingremains
possible. Finally, only 46% of the partici-
pants who attended the initial visit were
included in the present analysis. Those
who were included were signiﬁcantly
younger, more educated and active, and
more likely to be Caucasian. They were
lesslikelytosmokeandhavehypertension,
and they had lower BMI and WC, lower
baseline FPG and triglyceride levels, and
higher serum 25OHD and calcium intake.
However, a number of strengths of our
study should be highlighted. First, the use
ofOGTTtodiagnosediabetesensuredthat
all incident cases were included. Second,
serum 25OHD levels were measured in
the entire population at baseline. Third,
the AusDiab study was speciﬁcally de-
signed to identify a comprehensive range
of risk factors for diabetes in a representa-
tive sample of the Australian population,
which were directly measured or assessed
using validated techniques.
In conclusion, we found that higher
serum 25OHD concentrations, but not
dietary calcium intakes, were associated
with a reduced risk of developing type 2
diabetes at 5 years in Australian adults
aged $25 years independently of known
risk factors for diabetes. Although these
ﬁndingsneedtobeconﬁrmedinrandom-
ized controlled trials of vitamin D supple-
mentation,furtherstudiesarealsoneeded
to determine whether there is an optimal
serum 25OHD concentration above
which type 2 diabetes risk is reduced.
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